Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05039073
Title Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Emory University
Indications

Hodgkin's lymphoma

Therapies

Brentuximab vedotin + Nivolumab

Age Groups: adult | child | senior
Covered Countries USA


No variant requirements are available.